Vanda Pharmaceuticals Inc (VNDA.OQ)
27 Mar 2015
- Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching.
March 4 - Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching.
March 4 - Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching, sending its shares down 8.7 percent in after-hours trading.
|Takeda Pharmaceutical Co Ltd (4502.T)||¥6,111||-134.00|
|Sumitomo Dainippon Pharma Co Ltd (4506.T)||¥1,429||-48.00|
|Pfizer Inc. (PFE.N)||$34.53||+0.37|
|Merck & Co., Inc. (MRK.N)||$57.75||+0.15|
|Sanofi SA (SASY.PA)||€91.69||+0.31|
|AstraZeneca plc (AZN.L)||4,686.00p||-5.00|
|Eli Lilly and Co (LLY.N)||$73.58||+0.14|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (VNDA). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Vanda Pharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: Ford Investor Services, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.